ReBio Pharma Announces the Successful Completion of Seed Financing.

Turku, Finland, 13 November 2018 - ReBio Technologies Ltd. (“ReBio Pharma”, “ReBio”, or the “Company”) announced today that it closed a $2 million seed round, and welcomed WI Harper (WIH) as new investors. ReBio is an early stage biotechnology company that has developed SiSu®, a proprietary sustained-release pharmaceutical formulation platform, and is further leveraging its bioresorbable polymer development expertise to produce first-in class materials for medical device applications.

“ReBio’s groundbreaking advancements in polymer development shows promise in addressing multiple underserved areas within both drug delivery and medical device manufacture,” said [WI Harper]. “ReBio represents an important addition to WI Harper’s growing healthcare portfolio.”

Jonathan Glen, founder of ReBio, said, “We are excited to have WI Harper as a Shareholder. We look forward to leverage their extensive knowledge and network in Healthcare.”